SPHK1 and obesity due to melanocortin 4 receptor deficiency: Targeting the SphK1/S1P/S1PR1 axis with specific drugs can reduce tumor progression caused by key proinflammatory cytokines, macrophage infiltration, and obesity (Nagahashi et al., 2018).